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1. INTRODUCTION {#bcpt13289-sec-0001}
===============

Glucose‐dependent insulinotropic polypeptide (GIP) is a 42 amino acid long peptide hormone that is secreted from enteroendocrine K cells located in the proximal part of the small intestine in response to food intake.[1](#bcpt13289-bib-0001){ref-type="ref"} As an incretin hormone, it stimulates insulin release after a meal; however, in contrast to glucagon‐like peptide‐1 (GLP‐1) it acts glucagonotropic at low blood glucose levels.[2](#bcpt13289-bib-0002){ref-type="ref"}, [3](#bcpt13289-bib-0003){ref-type="ref"} GIP also displays a bone‐protective role as it both decreases bone resorption and increases bone formation.[4](#bcpt13289-bib-0004){ref-type="ref"}, [5](#bcpt13289-bib-0005){ref-type="ref"}, [6](#bcpt13289-bib-0006){ref-type="ref"}, [7](#bcpt13289-bib-0007){ref-type="ref"}, [8](#bcpt13289-bib-0008){ref-type="ref"} In addition, the use of a GIP analogue has been shown to improve bone strength in ovariectomized mice.[9](#bcpt13289-bib-0009){ref-type="ref"} The GIP receptor (GIPR) is a G protein‐coupled receptor (GPCR) belonging to subclass B1 of the GPCR family.[10](#bcpt13289-bib-0010){ref-type="ref"} In contrast to GLP‐1, the glucose‐lowering effect of GIP is impaired in patients with type 2 diabetes mellitus (T2DM), but the exact mechanism behind this remains to be described since the secretion of GIP seems normal or even elevated.[11](#bcpt13289-bib-0011){ref-type="ref"}, [12](#bcpt13289-bib-0012){ref-type="ref"}, [13](#bcpt13289-bib-0013){ref-type="ref"}, [14](#bcpt13289-bib-0014){ref-type="ref"} It has been hypothesized that the GIPR might be desensitized in the beta cells of patients with T2DM based on studies in diabetic rats,[15](#bcpt13289-bib-0015){ref-type="ref"} but this remains to be proven in humans. Previously described differences between the rodent and human GIP system exemplifies the necessity for studies on the human GIPR.[16](#bcpt13289-bib-0016){ref-type="ref"}, [17](#bcpt13289-bib-0017){ref-type="ref"} Interestingly, it has been shown that the GIPR function in bone metabolism of patients with T2DM is not abolished,[18](#bcpt13289-bib-0018){ref-type="ref"} which may point towards a cell, tissue and possibly species‐specific down‐regulation.

Owing to the impaired insulinotropic action of GIP in patients with T2DM,[11](#bcpt13289-bib-0011){ref-type="ref"}, [12](#bcpt13289-bib-0012){ref-type="ref"}, [13](#bcpt13289-bib-0013){ref-type="ref"}, [14](#bcpt13289-bib-0014){ref-type="ref"} the development of GIPR agonists has not been as successful as the development of GLP‐1 receptor (GLP‐1R) agonists.[19](#bcpt13289-bib-0019){ref-type="ref"}, [20](#bcpt13289-bib-0020){ref-type="ref"} In fact, it has been suggested[21](#bcpt13289-bib-0021){ref-type="ref"} and also experimentally verified in rodents and non‐human primates[22](#bcpt13289-bib-0022){ref-type="ref"} that GIPR antagonists are useful in the treatment of T2DM and obesity possibly due to a resensitization of the GIP system and thereby phenocopying functional agonism. However, the GIP system is more complex in terms of pharmacological targeting. Thus, a recent phase 2 study demonstrated that a dual GIPR and GLP‐1R agonist provided improved glucose control and weight loss than therapy with a GLP‐1 agonist, suggesting that GIPR agonists may have a role in the treatment of T2DM and obesity (at least in combination with GLP‐1R agonists).[23](#bcpt13289-bib-0023){ref-type="ref"}

Several naturally occurring amino acid variants of the GIPR have been discovered in the human population.[24](#bcpt13289-bib-0024){ref-type="ref"} The GIPR variant, \[E354Q\], is quite common with an allele frequency of 0.2.[25](#bcpt13289-bib-0025){ref-type="ref"} It was described for the first time in 1998, where homozygous carriers of the variant were reported to have decreased levels in serum C‐peptide concentrations (14% during fasting and 11% decrease after oral glucose tolerance test \[OGTT\]).[26](#bcpt13289-bib-0026){ref-type="ref"} This was confirmed in another study, where homozygous carriers had slightly increased plasma glucose (0.15 mmol/L) 2 hours after glucose ingestion as well as lower insulin secretion after an OGTT.[27](#bcpt13289-bib-0027){ref-type="ref"} In contrast to the relatively weak effect on blood glucose, a stronger phenotype is observed in bone homeostasis as homozygous carriers of GIPR‐\[E354Q\] have lower bone mineral density (BMD) and more than 50% increased fracture risk.[28](#bcpt13289-bib-0028){ref-type="ref"} Several in vitro studies have been presented, yet with diverging results (summarized in Table 2). One study in Chinese hamster fibroblasts (CHL) revealed an increased cAMP accumulation for \[E354Q\].[26](#bcpt13289-bib-0026){ref-type="ref"} Another study suggested decreased basal activity through G~αs~ in HEK293 cells,[24](#bcpt13289-bib-0024){ref-type="ref"} whereas a third study presented no difference in cAMP accumulation between GIPR wt and \[E354Q\] upon expression in HEK293 cells[29](#bcpt13289-bib-0029){ref-type="ref"} or CHO cells.[30](#bcpt13289-bib-0030){ref-type="ref"} In addition, it has been reported that GIPR‐\[E354Q\] have an increased GIP‐induced desensitization caused by an impaired exocytosis of internalized receptors.[29](#bcpt13289-bib-0029){ref-type="ref"} In the present study, we used in vitro and in silico methods to characterize GIPR‐\[E354Q\] in terms of ligand‐receptor binding kinetics and receptor‐ligand interaction, signalling through different pathways and internalization pattern to determine whether any of these basic pharmacological properties could explain the altered phenotypes of persons homozygous for GIPR‐\[E354Q\]. In broader terms, studies of GIPR variants may contribute to an enhanced understanding of the pharmacological potential of the GIP system and the mode‐of‐intervention for future drugs targeting the GIPR.

2. MATERIALS AND METHODS {#bcpt13289-sec-0002}
========================

The study was conducted in accordance with the Basic & Clinical Pharmacology & Toxicology policy for experimental and clinical studies.[31](#bcpt13289-bib-0031){ref-type="ref"}

2.1. Materials {#bcpt13289-sec-0003}
--------------

Human GIP(1‐42) was purchased from Bachem, Bubendorf, Switzerland (H5645). cDNA of human GIPR wt and GIPR‐\[E354Q\] were inserted in the pCMV‐Tag2B vector. Human SNAP‐GIPR was ordered and synthesized by Cisbio, Codolet, France, and inserted in pcDNA 3.1. SNAP‐GIPR‐\[E354Q\] was created by Quick Change Mutagenesis using the primers: GGTGTCCACCAGGTGGTGTTTGC (forward) and GCAAACACCACCTGGTGGACACC (reverse). The ^125^I‐labelled human GIP(1‐42) was purchased from PerkinElmer, Skovlunde, Denmark (NEX402025UC). Tag‐Lite SNAP‐Lumi4‐Tb was purchased from Cisbio, Codolet, France (SSNPTBX) and Fluorescein‐O'‐acetic acid from Sigma‐Aldrich, Broendby, Denmark (88596‐5MG‐F).

2.2. Transfection and tissue culture {#bcpt13289-sec-0004}
------------------------------------

COS‐7 cells were cultured at 10% CO~2~ and 37°C in Dulbecco\'s Modified Eagle Medium (DMEM) 1885 supplemented with 10% foetal bovine serum (FBS), 2 mmol/L glutamine, 180 units/mL penicillin and 45 g/mL streptomycin. HEK293 cells were cultured at 10% CO~2~ and 37°C in DMEM‐GlutaMAX™‐I supplemented with 10% FBS, 180 units/mL penicillin and 45 g/mL streptomycin. Both cell types were transfected using the calcium phosphate precipitation method.[32](#bcpt13289-bib-0032){ref-type="ref"} Transiently transfected COS‐7 cells were used in homologous competition binding, association and dissociation studies. Transiently transfected HEK293 cells were used for cAMP accumulation, β‐arrestin 2 recruitment and real‐time internalization experiments.

2.3. Membrane preparation {#bcpt13289-sec-0005}
-------------------------

Human GIPR wt, GIPR‐\[E354Q\] and pcDNA3.1 membranes were prepared through several centrifugation steps of COS‐7 cells expressing the corresponding receptor. The cells were scraped with PBS supplemented with a cOmplete™ protease inhibitor (Roche, Basel, Switzerland) and then homogenized using a Dounce. The homogenate was centrifuged for 3 minutes at 54 *g* (4°C), and subsequently, the supernatant of this homogenate was centrifuged for 45 minutes at 21 036 *g* at (4°C). The pellet was resuspended in storage buffer (20 mmol/L HEPES buffer (pH 7.2), 0.4 mmol/L CaCl~2~, 2 mmol/L MgCl~2~ and cOmplete™ protease inhibitor) and stored at −80°C. Protein determination was performed according to a standard Pierce™ BCA protein assay protocol (Thermo Scientific).

2.4. Homologous competition binding assay {#bcpt13289-sec-0006}
-----------------------------------------

Transiently transfected COS‐7 cells expressing either human GIPR wt or GIPR‐\[E354Q\] were seeded in clear 96‐well plates 1 day after transfection. The number of cells added per well was adjusted aiming for 5%‐10% specific binding of ^125^I‐GIP(1‐42). The next day, cells were assayed by competition binding for 3 hours at 4°C using \~15‐40 pM of ^125^I‐GIP(1‐42) and increasing concentrations of GIP(1‐42) in binding buffer (50 mmol/L HEPES buffer, pH 7.2, supplemented with 0.5% bovine serum albumin \[BSA\]). After incubation, the cells were washed twice in ice‐cold binding buffer and lysed using 200 mmol/L NaOH with 1% SDS for 30 minutes. The samples were analysed by the Wallac Wizard 1470 Gamma Counter.

2.5. Radioligand association and dissociation assay {#bcpt13289-sec-0007}
---------------------------------------------------

The association assay was executed by preparing a mixture of 30 µg human GIPR wt, GIPR‐\[E354Q\] or pcDNA3.1 and 0.5 µg wheatgerm agglutinin‐coated (WGA) PVT SPA beads (Perkin Elmer). This mixture was subsequently pre‐coupled on a shaker in a total volume of 50 µL binding buffer (50 mmol/L HEPES buffer (pH 7.2), supplemented with 1 mmol/L CaCl~2~, 5 mmol/L MgCl~2~ and 0.5% (w/v) BSA) for 30 minutes at 30°C. The pre‐coupling was followed by the distribution of membrane suspension in a CulturPlate‐96 (Perkin Elmer, Groningen, The Netherlands) in a total volume of 90 µL binding buffer and spun down afterwards (1500 rpm, 5 minutes, RT). The reaction was initiated by the addition of \~42 pmol/L ^125^I‐GIP(1‐42), and the amount of radioligand bound to receptor was measured every minute up to 100 minutes at 30°C using a TopCount NXT Microplate Scintillation & Luminescence Counter (Packard). For the dissociation experiment, the membrane suspension was distributed in a total volume of 85 µL binding buffer. The mixture was then pre‐incubated for 100 minutes at 30°C with ^125^I‐GIP(1‐42). The dissociation was initiated by adding 5 µL of 1 µmol/L unlabelled GIP(1‐42). The amount of radioligand bound to receptor was measured every minute up to 999 minutes.

2.6. cAMP and β‐arrestin 2 assay {#bcpt13289-sec-0008}
--------------------------------

For the cAMP assay, HEK293 cells were transiently transfected with either GIPR wt or GIPR‐\[E354Q\] and the bioluminescence resonance energy transfer (BRET) Epac‐based sensor for cAMP, CAMYEL (cAMP sensor using YFP‐Epac‐RLuc).[33](#bcpt13289-bib-0033){ref-type="ref"} For the β‐arrestin 2 assay, HEK293 cells were transiently transfected with either GIPR wt or GIPR‐\[E354Q\] and the donor Rluc8‐Arrestin‐3‐Sp1, the acceptor mem‐linker‐citrine‐SH3 and the GPCR kinase 2, GRK2 to facilitate β‐arrestin 2 recruitment.[34](#bcpt13289-bib-0034){ref-type="ref"} Two days following transfection, the cells were washed with PBS and resuspended in PBS with 5 mmol/L glucose. Then, 85 µL of the cell suspension solution was added to each well of a black‐white 96‐well isoplate followed by the addition of PBS with 5 µmol/L coelenterazine‐h. Following a 10‐minute. incubation, increasing concentrations of GIP(1‐42) were added and incubated for an additional 30 minutes. Luminescence was measured by the Berthold Technologies Mithras Multilabel Reader (Rluc8 at 485 ± 40 nm and YFP at 530 ± 25 nm).

2.7. Real‐time internalization assay {#bcpt13289-sec-0009}
------------------------------------

The assay was performed as previously described.[35](#bcpt13289-bib-0035){ref-type="ref"}, [36](#bcpt13289-bib-0036){ref-type="ref"} In short, HEK293 cells transiently expressing the human SNAP‐GIPR or SNAP‐GIPR‐\[E354Q\] were seeded in white 384‐well plates the day after transfection at a density of 25 000 cells/well. The next day, the media was removed and SNAP‐GIPR and SNAP‐GIPR‐\[E354Q\] were labelled with 100 nmol/L Tag‐Lite SNAP‐Lumi4‐Tb (donor) in OptiMEM for 60 minutes at 37°C. Afterwards, the cells were washed with HBBS supplemented with internalization buffer (1 mmol/L CaCl~2~, 1 mmol/L MgCl~2~, 20 mmol/L HEPES and 0.1% Pluronic F‐68, pH 7.4) followed by addition of 100 µmol/L pre‐heated fluorescein‐O'‐acetic acid (acceptor). The plate was placed in a 37°C incubator for 5 minutes prior to ligand addition to adjust the temperature. Then, the cells were stimulated with 37°C pre‐heated human GIP(1‐42) and internalization was measured every 3 minutes for 60 minutes at 37°C in PerkinElmer™ EnVision 2014 Multilabel Reader. The internalization data were corrected for any receptor expression differences by the ratio discrepancy between the two receptors.

2.8. Molecular dynamics simulation of the GIPR {#bcpt13289-sec-0010}
----------------------------------------------

Since no crystal structures or cryo‐EM structures of the full‐length GIPR are available, a homology model of GIPR in complex with the naturally occurring agonist GIP(1‐42) was made. This chimeric homology model was assembled using the cryo‐EM structure of the activated GLP‐1R [37](#bcpt13289-bib-0037){ref-type="ref"} (residues 128‐411, PDB: 5VAI, homology = 53%), the crystal structure of the extracellular domain of human GIPR [38](#bcpt13289-bib-0038){ref-type="ref"} (*r* residues 29‐122) and the NMR solution structure of GIP(1‐42), [39](#bcpt13289-bib-0039){ref-type="ref"} and missing residues 123‐127 were taken from the GPCRdb.[40](#bcpt13289-bib-0040){ref-type="ref"} Alignment of the receptor in the membrane was determined using the OPM database [41](#bcpt13289-bib-0041){ref-type="ref"} after which the receptor was inserted in a hexagonal lipid bilayer using the CHARMM‐GUI membrane builder consisting of 150 1‐palmitoyl‐2‐oleoyl‐sn‐glycero‐3‐phosphocholine (POPC) lipids.[42](#bcpt13289-bib-0042){ref-type="ref"} The receptor and membrane were dissolved in water with physiological salt concentration (0.15 mol/L) resulting in a system size of approximately 80k atoms with a x/y radius of 8.5 nm and a height of 13 nm. The system was equilibrated in a NPT ensemble at 310 K for 150 ns after which it was simulated for 600 ns using the same ensemble and temperature with GROMACS 2018.3 as the MD engine.[43](#bcpt13289-bib-0043){ref-type="ref"} The CHARMM36m force field was employed with TIP3P water molecules and a van der Waals cut‐off radius of 1.2 nm.[44](#bcpt13289-bib-0044){ref-type="ref"} All data analysis was performed using GROMACS tools and home‐made scripts. The wild‐type snapshot in Figure [1](#bcpt13289-fig-0001){ref-type="fig"} is taken from the MD simulation. The \[E354Q\] image is mutated using PyMol only to visualize that the mutation from glutamic acid to glutamine allows for preservation of the hydrogen bond interaction between the carbonyl and N‐terminal nitrogen.

![Illustration of GIPR wt and GIPR‐\[E354Q\]. The mutation of GIPR‐\[E354Q\] is located within the sixth transmembrane helix of the receptor. The genotype distribution among Europeans is 63% wild‐type, 33% heterozygous and 4% homozygous[25](#bcpt13289-bib-0025){ref-type="ref"}](BCPT-126-122-g001){#bcpt13289-fig-0001}

2.9. Data and statistical analysis {#bcpt13289-sec-0011}
----------------------------------

Kinetic binding parameters and *IC* ~50~ and *EC* ~50~ values were determined by non‐linear regression using GraphPad Prism 7 & 8. Sigmoid curves were fitted logistically with a Hill slope of 1 or −1 for the activation or binding curves, respectively. Internalization rates were determined by one‐phase association analysis using GraphPad Prism 7. The observed rate constants *K* ~obs~ (minute^−1^) of ^125^I‐GIP(1‐42) to GIPR wt and \[E543Q\] were obtained by plotting the data to a one‐phase association model. The dissociation rate constants *K* ~off~ (minute^−1^) were acquired by plotting data to a two‐phase decay model. The association rate constants for each phase *K* ~on\ (phase)~ (nmol/L^−1^ minute^−1^) were calculated according to the following equation:$$K_{\text{on\ (phase)}} = \frac{K_{\text{obs}} - K_{\text{off\ (phase)}}}{\lbrack L\rbrack}$$

In which \[*L*\] is the ligand concentration in nmol/L. To correct for the one‐phase association, a single *K* ~on~ (nmol/L^−1^ minute^−1^) value, covering both phases of the dissociation rate (*K* ~on\ (slow)~ and *K* ~on\ (fast)~)*,* was calculated as follows:$$K_{\text{on}} = K_{\text{on\ (fast)}}{} \ast \%\text{fast} + K_{\text{on\ (slow)}}{} \ast \%\text{slow}$$wherein %fast is the contribution of *K* ~off\ (fast)~ to the association rate constant and %slow is the contribution of *K* ~off\ (slow)~ to the association rate constant. The residence time (RT) in minutes was acquired as follows:$$\text{RT} = \frac{1}{K_{\text{off\ (phase)}}}$$

*EC* ~50~ and *E* ~max~ values and binding parameters were compared by an unpaired Student *t* test. Internalization rates were compared by a one‐way ANOVA with multiple comparisons. In both tests, *P* \< .05 was considered significant different.

3. RESULTS {#bcpt13289-sec-0012}
==========

The GIPR variant \[E354Q\] is quite common in the human population with the genotype distribution of 63% wt, 33% heterozygous carriers and 4% homozygous carriers.[25](#bcpt13289-bib-0025){ref-type="ref"} It is located in the sixth transmembrane domain of the receptor close to the extracellular site (Figure [1](#bcpt13289-fig-0001){ref-type="fig"}). To gain understanding of where in the receptor E354 is situated and what its role is in ligand binding, we decided to employ molecular dynamic (MD) simulation to study the GIPR in complex with the endogenous agonist GIP(1‐42). Hydrogen bond analysis of the MD simulations shows that the N‐terminal nitrogen of GIP(1‐42) forms a salt bridge with the carboxylic acid of E354 for approximately 78% of the simulated time indicating the importance of the interaction. The loss of the E354\'s anionic character upon mutation to a glutamine (Q) could perhaps weaken the interaction, but will still allow for a hydrogen bond in the same place, which might explain why previous studies described only little alteration in binding affinity.[24](#bcpt13289-bib-0024){ref-type="ref"}, [26](#bcpt13289-bib-0026){ref-type="ref"}

3.1. Similar binding affinity but altered binding kinetics of GIP(1‐42) on GIPR‐\[E354Q\] {#bcpt13289-sec-0013}
-----------------------------------------------------------------------------------------

Inspired by the predicted slightly altered binding profile in \[E354Q\], we moved on with in vitro analyses of ligand binding and receptor activation. Homologous competition binding done at 4°C using ^125^I‐GIP(1‐42) showed no difference in the affinity of GIP(1‐42) to the GIPR wt and GIPR‐\[E354Q\] with *K* ~d~ of 2.39 ± 0.18 and 2.08 ± 0.12 nmol/L, respectively (Figure [2](#bcpt13289-fig-0002){ref-type="fig"}A, Table [1](#bcpt13289-tbl-0001){ref-type="table"}). Moreover, no difference was observed in the *B* ~max~ values (Figure [2](#bcpt13289-fig-0002){ref-type="fig"}B). To determine whether the predicted altered binding mode in \[E354Q\] would change the binding kinetics, we measured association and dissociation rates of ^125^I‐GIP(1‐42) using membranes from COS‐7 cells expressing either of the receptors. The experiments were done at 30°C, and the kinetic profiles of the association of ^125^I‐GIP(1‐42) were best fitted with a one‐phase model with saturation reached after approximately 60 minutes for both receptors (Figure [2](#bcpt13289-fig-0002){ref-type="fig"}C). The observed on‐rates (*K* ~obs~) for GIPR wt and GIPR‐\[E354Q\] were 0.076 ± 0.006 and 0.073 ± 0.011 minute^−1^, emphasizing that ^125^I‐GIP(1‐42) binds with similar *K* ~obs~ to both receptors. After obtained equilibrium, we could reverse the binding of ^125^I‐GIP(1‐42) by the addition of 1 μmol/L unlabelled GIP(1‐42), and the corresponding dissociation profiles were best fitted with a two‐phase decay model with a fast and a slow phase (%*fast phase* 62% ± 2% and 64% ± 1%, respectively; Figure [2](#bcpt13289-fig-0002){ref-type="fig"}D). Interestingly, no complete dissociation of ^125^I‐GIP(1‐42) was obtained, as a plateau was reached at approximately 15% remaining ^125^I‐GIP(1‐42) binding on both receptors. As the off‐rate was slower for GIPR‐\[E354Q\], the residence time (*RT*; defined as the reciprocal value of *K* ~off~ [45](#bcpt13289-bib-0045){ref-type="ref"}) of ^125^I‐GIP(1‐42) was higher than that of GIPR wt, both when calculated from the fast off‐rate, RT~(fast)~ 26.41 ± 0.74 versus 33.12 ± 1.57 min (*P* = .018), and from the slow off‐rate RT~(slow)~ 225.38 ± 3.12 versus 267.03 ± 10.13 min (*P* = .017; Table [1](#bcpt13289-tbl-0001){ref-type="table"}).

![Binding affinity and kinetics of GIP(1‐42) to GIPR wt and GIPR‐\[E354Q\]. A, COS‐7 cells were transiently transfected with human GIPR wt and GIPR‐\[E354Q\] and assayed for homologous competition binding using ^125^I‐GIP(1‐42) as radioligand and increasing concentrations of GIP(1‐42). Data are normalized to the specific binding of the GIPR wt. B, The B~max~ value was calculated for both GIPR wt and GIPR‐\[E354Q\] from the homologous competition binding data. For the association (C) and dissociation (D) experiments of ^125^I‐GIP(1‐42), membranes of COS‐7 cells expressing GIPR wt or GIPR‐\[E354Q\] were used. Data are normalized to the specific binding of each receptor. Data are shown as mean ± SEM, n ≥ 3 independent experiments carried out in duplicates](BCPT-126-122-g002){#bcpt13289-fig-0002}

###### 

Binding parameters of ^125^I‐GIP(1‐42) to GIPR wt and GIPR‐\[E354Q\]

                                 GIPR wt           GIPR‐\[E354Q\]
  ------------------------------ ----------------- ------------------
  *K* ~D~ (nmol/L)               2.39 ± 0.18       2.08 ± 0.12
  *K* ~obs~ (min^−1^)            0.076 + 0.006     0.073 ± 0.011
  *K* ~off\ (fast)~ (min^−1^)    0.034 ± 0.006     0.030 ± 0.007
  *K* ~off\ (slow)~ (min^−1^)    0.0044 ± 0.0001   0.0038 ± 0.0002
  \% fast phase                  62 ± 2            64 ± 1
  RT~(fast)~ (min)               26.41 ± 0.74      33.12 ± 1.57\*
  RT~(slow)~ (min)               225.38 ± 3.12     267.03 ± 10.13\*
  *K* ~on~ (nM^−1^ \* min^−1^)   1.283 ± 0.253     1.371 ± 0.378

The residence times were compared by an unpaired Student *t* test (\**P* \< .05).
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3.2. GIPR‐\[E354Q\] shows an increased cAMP signalling profile {#bcpt13289-sec-0014}
--------------------------------------------------------------

Next, we studied whether GIPR‐\[E354Q\] had a different signalling pattern compared with the GIPR wt. Several studies have previously described diverging signalling profiles of GIPR wt and \[E354Q\].[24](#bcpt13289-bib-0024){ref-type="ref"}, [26](#bcpt13289-bib-0026){ref-type="ref"}, [29](#bcpt13289-bib-0029){ref-type="ref"} We decided to use same cell type (HEK293 cells) and same signalling principle (BRET‐based assays) to determine signalling via G protein‐dependent and ‐independent pathways in order to avoid observational bias. Thus, we studied both cAMP accumulation and β‐arrestin 2 recruitment in HEK293 cells expressing either GIPR wt or GIPR‐\[E354Q\]. GIP(1‐42) was found to be slightly more potent and efficacious in cAMP accumulation on GIPR‐\[E354Q\] than GIPR wt with an *EC* ~50~ of 0.34 ± 0.088 pmol/L compared with 0.69 ± 0.047 pmol/L and *E* ~max~ of 137% ± 3.4% compared with 102% ± 1.7%, respectively (Figure [3](#bcpt13289-fig-0003){ref-type="fig"}A). In addition, GIPR‐\[E354Q\] had a higher basal cAMP activity than GIPR wt reaching 17.5 ± 3.0% of *E* ~max~ of GIPR wt. In contrast, no difference was observed in the ability of the receptors to recruit β‐arrestin 2 with an *EC* ~50~ of 5.5 ± 0.082 and 4.7 ± 0.23 nmol/L and *E* ~max~ of 99% ± 3.3% and 97% ± 8.6%, respectively, upon addition of GIP(1‐42) (Figure [3](#bcpt13289-fig-0003){ref-type="fig"}B).

![Human GIP(1‐42) concentration curves for cAMP accumulation and β‐arrestin 2 recruitment. HEK293 cells were transiently transfected with GIPR wt or GIPR‐\[E354Q\] and (A) the Epac‐based BRET sensor CAMYEL for cAMP accumulation or (B) the donor Rluc8‐Arrestin‐3‐Sp1, the acceptor mem‐linker‐citrine‐SH3 and the GPCR kinase 2 (GRK2) for β‐arrestin 2 recruitment. Data are shown as mean ± SEM, n = 3 independent experiments carried out in duplicates](BCPT-126-122-g003){#bcpt13289-fig-0003}

3.3. The GIPR‐\[E354Q\] internalizes with a faster rate than GIPR wt {#bcpt13289-sec-0015}
--------------------------------------------------------------------

Due to the increased cAMP accumulation for GIPR‐\[E354Q\], we went on and studied whether GIPR‐\[E354Q\] had an altered internalization pattern. Again, we used HEK293 cells. In order to measure the internalization in real‐time, we used SNAP‐tagged versions of both receptors. Since internalization is very dependent on receptor expression,[36](#bcpt13289-bib-0036){ref-type="ref"} the internalization data were corrected for any receptor expression differences measured by the donor signal. Both receptors were internalized after stimulation with 100 nmol/L and 1 µmol/L GIP(1‐42) (Figure [4](#bcpt13289-fig-0004){ref-type="fig"}A‐C); however, the GIPR‐\[E354Q\] displayed faster internalization than GIPR wt at both 100 nmol/L and 1 µmol/L GIP(1‐42) stimulation with the values of 0.086 ± 0.030 and 0.094 ± 0.011 compared with 0.037 ± 0.011 and 0.045 ± 0.006 minute^−1^, respectively. Notably, no statistical significant differences were observed in the internalization efficacy between the two receptors (~bs~AUC for 100 nmol/L GIP(1‐42) stimulation: 61 ± 8.0 and 76 ± 45 for GIPR wt and GIPR‐\[E354Q\], respectively, and ~bs~AUC for 1 µmol/L GIP(1‐42) stimulation: 97 ± 5.1 and 79 ± 55 for GIPR wt and GIPR‐\[E354Q\], respectively).

![Internalization of SNAP‐GIPR wt and SNAP‐GIPR‐\[E354Q\]. HEK293 cells were transiently transfected with SNAP‐GIPR (A) or SNAP‐GIPR‐\[E354Q\] (B) and assayed for internalization over time following stimulation of 100 nmol/L (■) or 1 μmol/L (●) GIP(1‐42). (C) A zoom of the first 25 min of internalization of SNAP‐GIPR and SNAP‐GIPR‐\[E354Q\] following 1 μmol/L GIP(1‐42) stimulation. Data are shown as mean ± SEM, n = 3 independent experiments carried out in triplicates](BCPT-126-122-g004){#bcpt13289-fig-0004}

4. DISCUSSION {#bcpt13289-sec-0016}
=============

Our study demonstrates that the naturally occurring GIPR variant, \[E354Q\], that results in long‐term impairment of the GIP system in humans and markedly increased fracture risk,[28](#bcpt13289-bib-0028){ref-type="ref"} displays an altered molecular pharmacological phenotype compared with wt receptor. We find an enhanced internalization rate possibly explained by an altered ligand‐binding mode, enhanced residence time and enhanced downstream signalling of the endogenous agonist GIP(1‐42). Together with the previously described impaired recycling of \[E354Q\],[29](#bcpt13289-bib-0029){ref-type="ref"} these findings suggest facilitated receptor desensitization and long‐term down‐regulation. This is highly relevant, as the GIP system seems more prone to desensitization as compared to the GLP‐1 system given the decline in the insulinotropic action of GIP (but not of GLP‐1) over time in patients with T2DM.[11](#bcpt13289-bib-0011){ref-type="ref"}, [12](#bcpt13289-bib-0012){ref-type="ref"}, [13](#bcpt13289-bib-0013){ref-type="ref"}, [14](#bcpt13289-bib-0014){ref-type="ref"} Thus, the phenotype of \[E354Q\] may represent the end‐stage activity of the 'normal' wt GIP system in T2DM and obesity where hyperglycaemia and enhanced levels of GIP may have contributed to receptor desensitization.

4.1. GIP(1‐42) shows altered efficacy and residence time on GIPR‐\[E354Q\] {#bcpt13289-sec-0017}
--------------------------------------------------------------------------

The residence time, that is the time in which a drug remains bound to its target, has become increasingly acknowledged as an important parameter in pharmacology due to its strong predictive value for in vivo pharmacological activity.[45](#bcpt13289-bib-0045){ref-type="ref"} The longer a certain drug occupies a receptor, the more profound effect is obtained, thus a higher efficacy may be reached.[46](#bcpt13289-bib-0046){ref-type="ref"} This has for instance been shown for the β~2~‐adrenoceptor agonist, C26, having a longer residence time and higher potency and efficacy in several distinct signalling pathways compared with the endogenous agonist adrenaline.[47](#bcpt13289-bib-0047){ref-type="ref"} Furthermore, it has been shown for three adenosine A~1~ receptor (A~1~R) agonists, all having similar affinity, but different binding kinetics, where the agonist (LUF6941) with the longest residence time had the greatest anti‐lipolytic effect in rat adipocytes.[48](#bcpt13289-bib-0048){ref-type="ref"} We found that GIP(1‐42) bound with the same affinity to GIPR wt and GIPR‐\[E354Q\] (Figure [2](#bcpt13289-fig-0002){ref-type="fig"}A). Looking further into the ligand‐binding kinetics, no differences were observed in the association rates, but the dissociation was slower for GIP(1‐42) on GIPR‐\[E5354Q\], which in turn revealed a higher residence time for the agonist binding to the this receptor (Table [1](#bcpt13289-tbl-0001){ref-type="table"}). This aligns very well with the enhanced cAMP activity observed for GIPR‐\[E354Q\] (Figure [3](#bcpt13289-fig-0003){ref-type="fig"}A), that, however, stands in contrast to a previous study describing the opposite (decreased cAMP) in HEK293 cells for GIPR‐\[E354Q\].[24](#bcpt13289-bib-0024){ref-type="ref"} This difference could be due to assay technicalities, as we used real‐time cAMP measurements, whereas the luciferase reporter gene assay used in Ref[24](#bcpt13289-bib-0024){ref-type="ref"} represents a downstream end‐point cAMP measurement. Given the faster internalization of GIPR‐\[E354Q\] (Figure [4](#bcpt13289-fig-0004){ref-type="fig"}B,C) and previously published decreased recycling leading to faster desensitization, it is likely that an end‐point measurement will reveal overall lower activity levels for GIPR‐\[E354Q\] as compared to wt receptor. Table [2](#bcpt13289-tbl-0002){ref-type="table"} provides a comprehensive overview of our data of GIPR‐\[E354Q\] in comparison with previously published data.

###### 

Overview of in vitro results of GIPR‐\[E354Q\] compared with GIPR wt

<table><thead><tr class="header"><th>References</th><th>Measurement</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></tr></thead><tbody><tr class="odd"><td>Present study</td><td>HEK293</td><td><p>Ligand stimulation for 4 h at 4°C.</p><p>Readout:</p><p><sup>125</sup>I‐GIP(1‐42) binding</p></td><td>No difference in binding affinity of GIP(1‐42)</td><td>HEK293</td><td><p>Ligand stimulation for 30 min.</p><p>Readout: BRET luminescence</p></td><td>↑ basal and maximal activity and higher potency of [E354Q]</td><td>HEK293</td><td><p>Labelling of SNAP‐tagged receptors</p><p>Readout:</p><p>Donor signal</p></td><td>A tendency for ↓ expression of [E354Q] (data not shown)</td><td>HEK293</td><td><p>Ligand added just before measurement</p><p>Read out:</p><p>Real‐time FRET</p></td><td>↑ internalization rate of [E354Q]</td><td> </td></tr><tr class="even"><td>Fortin et al <a href="#bcpt13289-bib-0024" data-ref-type="ref">24</a></td><td>HEK293</td><td><p>Ligand stimulation for 8h at 4°C.</p><p>Readout:</p><p><sup>125</sup>I‐GIP(1‐42) binding</p></td><td>No difference in binding affinity of GIP(1‐42)</td><td>HEK293</td><td><p>Ligand stimulation for 6 h.</p><p>Readout:</p><p>CRE‐Luc luciferase</p></td><td>↓ basal and maximal activity</td><td>HEK293</td><td><p>Labelling of HA‐tag</p><p>Readout:</p><p>ELISA</p></td><td>↓ surface expression of [E354Q]</td><td> </td><td> </td><td></td><td></td></tr><tr class="odd"><td>Almind et al <a href="#bcpt13289-bib-0026" data-ref-type="ref">26</a></td><td>CHL</td><td><p>Ligand stimulation for 4h at 4°C.</p><p>Readout:</p><p><sup>125</sup>I‐GIP(1‐42) binding</p></td><td>No difference in binding affinity of GIP(1‐42)</td><td>CHL</td><td><p>Ligand stimulation for 9 min</p><p>Readout:</p><p>Intracellular tritiated cAMP</p></td><td>↓ basal activity but ↑ potency of [E354Q]</td><td> </td><td> </td><td> </td><td></td><td></td><td></td><td></td></tr><tr class="even"><td>Mohammad et al <a href="#bcpt13289-bib-0029" data-ref-type="ref">29</a></td><td> </td><td><p>HEK293</p><p>3T3‐L1 adipocytes</p></td><td><p>Ligand stimulation for 15 min</p><p>Readout:</p><p>Immunoassay kit</p></td><td>No difference in activity</td><td>3T3‐L1 adipocytes</td><td><p>Labelling of HA‐tag</p><p>Readout:</p><p>Immunofluorescence of fixed, non‐permeabilized cells</p></td><td>No difference in expression</td><td>3T3‐L1 adipocytes</td><td><p>Ligand stimulation for different time points.</p><p>Readout:</p><p>Anti‐HA labelling of fixed cells</p></td><td>No difference in internalization rate</td><td>3T3‐L1 adipocytes</td><td><p>Ligand stimulation for different time points.</p><p>Readout:</p><p>Anti‐HA labelling of fixed cells</p></td><td>↓ exocytosis rate of [E354Q]</td></tr><tr class="odd"><td>Kubota et al <a href="#bcpt13289-bib-0030" data-ref-type="ref">30</a></td><td> </td><td>CHO</td><td><p>Ligand stimulation time not given.</p><p>Readout:</p><p>Radioimmunoassay kit</p></td><td>No difference in activity</td><td> </td><td> </td><td> </td><td></td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table>

The table displays an overview of our results and previously published in vitro results of GIPR‐\[E354Q\]. Within each experiment, GIPR‐\[E354Q\] is compared to GIPR wt.
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4.2. High potency for agonist‐induced cAMP accumulation relative to arrestin recruitment and affinity {#bcpt13289-sec-0018}
-----------------------------------------------------------------------------------------------------

Pharmacological characterizations of ligands for GPCRs include determination of affinity under equilibrium conditions (eg the *IC* ~50~ value or *K* ~D~) and signalling activity (potency (*EC* ~50~) and efficacy (*E* ~max~)).[45](#bcpt13289-bib-0045){ref-type="ref"} We observed a huge preference towards G protein activation compared with arrestin recruitment with 8000‐ to 14 000‐fold higher potency of GIP(1‐42)‐induced cAMP accumulation in the two GIP receptors (Figure [3](#bcpt13289-fig-0003){ref-type="fig"}). This is in accordance with our previously published potency differences for the GIP receptor [35](#bcpt13289-bib-0035){ref-type="ref"} and for the closely related GLP‐1 receptor.[49](#bcpt13289-bib-0049){ref-type="ref"}, [50](#bcpt13289-bib-0050){ref-type="ref"} The same pattern was observed for the glucagon receptor (GCGR), though with a less pronounced difference.[49](#bcpt13289-bib-0049){ref-type="ref"} A contributing factor to the higher potency observed for class B1 receptors to induce cAMP accumulation could be downstream amplification of G~αs~ which is not the case for β‐arrestin recruitment and internalization. However, as other G~αs~‐coupled receptors, such as class A receptors, like the adrenergic receptors do not display such bias towards G~αs~ over arrestin recruitment, it could also reflect that G~αs~ is the main signalling pathway during physiological control. A similar difference (3000‐6000‐fold) was observed when comparing the nanomolar binding affinity (*K* ~D~) to the picomolar potency (*EC* ~50~) in cAMP accumulation, again, a general tendency for ligands of class B GPCRs[51](#bcpt13289-bib-0051){ref-type="ref"}, [52](#bcpt13289-bib-0052){ref-type="ref"} and a phenomenon that ensures receptor signalling even with very little occupancy. This suggests the presence of spare receptors, that is a surplus of receptors relative to the occupancy needed for signalling output,[53](#bcpt13289-bib-0053){ref-type="ref"} and could reflect the high importance of receptor signalling in human health (such as blood glucose regulation among other roles for the incretin receptors). It is, however, also likely that the downstream amplification of cAMP contributes to the potency:affinity difference.

4.3. GIPR desensitization and signalling from endosomes {#bcpt13289-sec-0019}
-------------------------------------------------------

It is well known that the insulinotropic action of GIP is diminished in patients with T2DM[11](#bcpt13289-bib-0011){ref-type="ref"}, [12](#bcpt13289-bib-0012){ref-type="ref"}, [13](#bcpt13289-bib-0013){ref-type="ref"}, [14](#bcpt13289-bib-0014){ref-type="ref"}; however, the exact mechanism for this is not known. Maintained high plasma levels of GIP in patients with T2DM exclude lack of ligand to explain the diminished effect.[54](#bcpt13289-bib-0054){ref-type="ref"} It has, however, been suggested that an increased GIPR desensitization in the beta cell could be involved in the impaired response of GIP to hyperglycaemia in patients with T2DM (as reported in diabetic rats[15](#bcpt13289-bib-0015){ref-type="ref"}) or that downstream GIPR signalling is altered in the beta cells.[55](#bcpt13289-bib-0055){ref-type="ref"} We have previously shown that the GIPR internalizes in a low‐potent, β‐arrestin‐dependent manner with equal importance of β‐arrestin 1 and β‐arrestin 2 and only minimum internalization in the absence of arrestins.[35](#bcpt13289-bib-0035){ref-type="ref"} The low‐potent internalization observed for GIPR and for other class B GPCRs thus aligns well with the low‐potent β‐arrestin recruitment for these receptors as observed in for instance the GLP‐1R and the GCGR.[50](#bcpt13289-bib-0050){ref-type="ref"}, [56](#bcpt13289-bib-0056){ref-type="ref"} Here, we describe that the GIPR variant \[E354Q\] internalizes faster than the wt receptor (Figure [4](#bcpt13289-fig-0004){ref-type="fig"}B) possibly caused by altered agonist binding mode and kinetics with the increased residence time of the agonist (and a subsequent higher cAMP‐mediated signalling which for the GIPR has been reported to also occur intracellularly from GIPR expressed in endosomes[57](#bcpt13289-bib-0057){ref-type="ref"}). Together with the reported impaired exocytosis of GIPR‐\[E354Q\],[29](#bcpt13289-bib-0029){ref-type="ref"} the increased internalization will contribute to receptor desensitization and down‐regulation over time (Figure [5](#bcpt13289-fig-0005){ref-type="fig"}). Thus, the impaired recovery of GIPR‐\[E354Q\] may over time lead to an impaired response of GIP resulting in the altered bone homeostasis and blood glucose control in E354Q carriers. This resembles the suggested desensitization of the wt GIP system in patients with T2DM, and it can therefore be hypothesized that the increased desensitization of GIPR‐\[E354Q\] mimics what happens over time in T2DM and that studies of the GIPR‐\[E354Q\] signalling might contribute to a better understanding of the decreased sensitivity of the wt GIP system in T2DM.

![Illustration of altered signalling mechanism of GIPR‐\[E354Q\] and possible link to long‐term consequences](BCPT-126-122-g005){#bcpt13289-fig-0005}
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